Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021186035 - CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY

Publication Number WO/2021/186035
Publication Date 23.09.2021
International Application No. PCT/EP2021/057094
International Filing Date 19.03.2021
IPC
A61K 38/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides
A61P 25/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07K 14/665 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
665derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
CPC
A61K 38/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides ; , e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
A61K 38/33
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
33derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applicants
  • MEDIZINISCHE UNIVERSITÄT WIEN [AT]/[AT]
Inventors
  • GRUBER, Christian
  • MURATSPAHIC, Edin
Agents
  • MEIER, Jürgen
Priority Data
20164576.920.03.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY
(FR) CYCLOTIDES EN COMBINAISON AVEC DES LIGANDS DU RÉCEPTEUR OPIOÏDE KAPPA POUR UNE THÉRAPIE DE LA SEP
Abstract
(EN) The present invention relates to a pharmaceutical composition comprising a cyclotide and a ligand of the kappa opioid receptor (the kOR), or a combination thereof, for use in treating Multiple Sclerosis (MS), in remyelination, in improving CNS lesions, in preventing or reducing demyelination and/or CNS lesions, and/or in treating pain, in particular neuropathic pain and/or pain resulting from/coming along with MS. The present invention further relates to a combination of a cyclotide and a ligand of the kOR and to a pharmaceutical composition comprising said combination. The present invention further relates to a use of a cyclotide for reducing adverse effects of a ligand of the kOR and/or for increasing the potency and/or efficacy of a ligand of the kOR. Further, the present invention relates to a kit comprising a cyclotide and a ligand of the kOR. The present invention further relates to a pharmaceutical composition as part of a kit, wherein a comprised cyclotide and ligand of the kOR are for use in treating MS and related diseases and/or symptoms. The present invention further relates to a kit comprising a pharmaceutical composition comprising a cyclotide and a ligand of the kOR, wherein said pharmaceutical composition and/or said cyclotide and ligand of the kOR is/are for use in treating MS and related diseases and/or symptoms. The invention further relates to (a) novel Viola-type cyclotide(s).
(FR) La présente invention concerne une composition pharmaceutique comprenant un cyclotide et un ligand du récepteur opioïde kappa (le kOR), ou une combinaison associée, pour une utilisation dans le traitement de la sclérose en plaques (SEP), dans la remyélinisation, dans l'amélioration des lésions du SNC, dans la prévention ou la réduction de la démyélinisation et/ou des lésions du SNC, et/ou dans le traitement de la douleur, en particulier de la douleur neuropathique et/ou de la douleur résultant de/venant conjointement avec la SEP. La présente invention concerne en outre une combinaison d'un cyclotide et d'un ligand du kOR et une composition pharmaceutique comprenant ladite combinaison. La présente invention concerne en outre l'utilisation d'un cyclotide pour réduire les effets secondaires d'un ligand du kOR et/ou pour augmenter l'activité et/ou l'efficacité d'un ligand du kOR. En outre, la présente invention concerne un kit comprenant une cyclotide et un ligand du kOR. La présente invention concerne en outre une composition pharmaceutique faisant partie d'un kit, dans lequel un cyclotide et un ligand du kOR compris sont destinés à être utilisés dans le traitement de la SEP et de maladies et/ou de symptômes associés. La présente invention concerne en outre un kit comprenant une composition pharmaceutique comprenant un cyclotide et un ligand du kOR, ladite composition pharmaceutique et/ou lesdits cyclotide et ligand du kOR étant destinés à être utilisés dans le traitement de la SEP et de maladies et/ou de symptômes associés. L'invention concerne en outre (a) un ou des nouveaux cyclotides de type Viola.
Latest bibliographic data on file with the International Bureau